Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, tolerability and immunogenicity of Bexsero in immunocompromised children and adolescents versus healthy controls
2013-002454-78Phase 4Completed
- Sponsor
- Novartis
- Start
- Dec 2013
- Countries
- 1
01
Overview
Phase 4, open-label trial of meningococcal group B vaccine in Meningococcal B infection, meningococcal disease and bacterial meningitis (2 arms), sponsored by Novartis. Primary endpoint: Safety and tolerability of two doses of Bexsero. Started Dec 2013; status: completed.
02
Drugs
meningococcal group B vaccine
03
Conditions
Meningococcal B infectionmeningococcal diseasebacterial meningitis
Beyond the preview
Go deeper on 2013-002454-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002454-78.